Key terms
About ADPT
Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson on September 8, 2009 and is headquartered in Seattle, WA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ADPT news
Apr 09
5:42pm ET
Adaptive Biotechnologies Names Kyle Piskel New CFO
Apr 09
6:26am ET
BTIG Sticks to Their Buy Rating for Adaptive Biotechnologies (ADPT)
Apr 04
7:12am ET
Adaptive Biotechnologies price target lowered to $5 from $6 at BTIG
Apr 04
7:10am ET
Analysts Offer Insights on Healthcare Companies: Arcellx Inc (ACLX) and Adaptive Biotechnologies (ADPT)
Apr 04
7:07am ET
Adaptive Biotechnologies sees Q1 revenue $41M-$43M, consensus $38.2M
Apr 04
7:07am ET
Adaptive Biotechnologies announces CFO transition
Apr 04
7:06am ET
Adaptive Biotechnologies concludes strategic review, will operate MRD internally
Apr 03
5:38am ET
J.P. Morgan Sticks to Its Buy Rating for Adaptive Biotechnologies (ADPT)
Apr 02
4:24pm ET
Adaptive Biotechnologies CFO Resigns, Successor Appointed
Apr 02
4:20pm ET
Adaptive Biotechnologies to host business news update conference call
Apr 02
4:55am ET
Adaptive Biotechnologies to host business news update conference call
Apr 01
10:00pm ET
Adaptive Biotechnologies to host business news update conference call
Feb 22
5:25am ET
BTIG Reaffirms Their Buy Rating on Adaptive Biotechnologies (ADPT)
Feb 20
7:27am ET
Adaptive Biotechnologies price target lowered to $5 from $6 at Piper Sandler
Feb 20
6:20am ET
Analysts’ Top Healthcare Picks: RxSight (RXST), Adaptive Biotechnologies (ADPT)
Feb 16
7:39am ET
Scotiabank Keeps Their Buy Rating on Adaptive Biotechnologies (ADPT)
Feb 16
7:26am ET
Adaptive Biotechnologies: Hold Rating Justified by Mixed Financial Results and Ongoing Strategic Review Uncertainty
Feb 15
9:03am ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
Feb 15
12:30am ET
Analysts Are Bullish on These Healthcare Stocks: Adaptive Biotechnologies (ADPT), Benitec Biopharma (BNTC)
Feb 14
4:19pm ET
Adaptive Biotechnologies sees FY24 operating expenses $360M-$370M
Feb 14
4:18pm ET
Adaptive Biotechnologies reports Q4 EPS (48c), consensus (33c)
Feb 12
5:46am ET
Adaptive Biotechnologies: Hold Rating Maintained Amid Cautious 2024 Financial Outlook
No recent press releases are available for ADPT
ADPT Financials
Key terms
Ad Feedback
ADPT Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ADPT Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range